1351478-20-0

Basic information

• Product Name: C₂₆H₂₉N₅O
• Synonyms: C₂₆H₂₉N₅O
• CAS NO: 1351478-20-0
• Molecular Weight: 427.549
• Mol File: 1351478-20-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₂₆H₂₉N₅O(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₆H₂₉N₅O(1351478-20-0)
• EPA Substance Registry System: C₂₆H₂₉N₅O(1351478-20-0)

Safety Data

• Hazardous Substances Data: 1351478-20-0(Hazardous Substances Data)

Upstream product

• 938043-30-2 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine 
• 1351478-18-6 5-bromo-3-(5-methoxy-pyridin-2-yl)-2-methyl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1351478-19-7 C₃₃H₃₅N₅O₃S 
• 1142944-78-2 (5-methoxypyridine-2-yl)boronic acid 
• 1351478-10-8 5-bromo-3-iodo-2-methyl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 875639-15-9 5-bromo-3-iodo-1-(4-methylbenzene-1-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 757978-18-0 3-iodo-5-bromo-1H-pyrrolo[2,3-b]-pyridine 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1351477-47-8 6-{2-methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-pyridin-3-ol 

Relevant articles and documents

MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES

Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.